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The cytotoxic T lymphocyte (CTL) response plays a key role in controlling viral infection,
but only a few epitopes within the HTNV glycoprotein (GP) that are recognized by
CTLs have been reported. In this study, we identified one murine HTNV GP-derived
H2-Kb-restricted CTL epitope in C57BL/6mice, which could be used to design preclinical
studies of vaccines for HTNV infection. First, 15 8-mer peptides were selected from
the HTNV GP amino acid sequence based on a percentile rank of <=1% by IEDB
which is the most comprehensive collection of epitope prediction and analysis tool.
A lower percentile rank indicates higher affinity and higher immune response. In the
case of the consensus method, we also evaluated the binding score of peptide-binding
affinity by the BIMAS software to confirm that all peptides were able to bind H2-Kb.
Second, one novel GP-derived CTL epitope, GP6 aa456-aa463 (ITSLFSLL), was
identified in the splenocytes of HTNV-infected mice using the IFN-γ ELISPOT assay.
Third, a single peptide vaccine was administered to C57BL/6 mice to evaluate the
immunogenic potential of the identified peptides. ELISPOT and cell-mediated cytotoxicity
assays showed that this peptide vaccine induced a strong IFN-γ response and potent
cytotoxicity in immunized mice. Last, we demonstrated that the peptide-vaccinated
mice had partial protection from challenge with HTNV. In conclusion, we identified an
H2-Kb-restricted CTL epitope with involvement in the host immune response to HTNV
infection.
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INTRODUCTION
Hantaan virus (HTNV), the prototype of the Hantavirus genus, is a rodent-borne pathogen that is
the major causative agent of hemorrhagic fever with renal syndrome (HFRS; Abbott et al., 1999).
The genome of HTNV consists of L, M, and S segments, which encode the viral RNA-dependent
RNA polymerase, glycoprotein, and nucleoprotein, respectively (Cheng et al., 2014). HFRS is a
severe, life-threatening illness characterized by fever, hemorrhage, and renal failure and is a serious
public health threat in China (Hansen et al., 2015). A total of 136,012 cases were reported during
2005–2015 in mainland China, with a case-fatality rate as high as 10–15% (Zhang et al., 2010; Kang
et al., 2012). To date, several types of inactivated vaccines targeting the pathogens that cause HFRS
have been licensed (Liu et al., 2016). However, these inactivated vaccines have many shortcomings,
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including poor immunogenicity, which hinders the production
of neutralizing antibodies or cell-mediated immunity (Song et al.,
1992), and the concern of safety when using inactivated vaccines,
which may contain some infectious particles. Furthermore,
there is no study reporting that it could establish long-term
memory immunity (Jiang et al., 2015). Thus, it is necessary to
develop an alternative immunotherapy strategy that can induce
robust humoral immune response to produce therapeutically
effective antiviral antibodies and T cell-mediated autoimmune
responses. However, epitope based vaccines represent a powerful
approach to induce a specific immune response against the
selected epitopes, avoiding the side effects of other unfavorable
epitopes in the complete antigen. What’s more, epitope based
vaccine has other considerable advantages, including increased
safety, the opportunity to engineer the epitopes rationally for
increased potency and breadth, and the ability to focus the
immune response on conserved epitopes CTL epitope-specific T
cell immunity demonstrate to be a long-term approach immune
strategy. Moreover, the epitope based vaccine approach has
been shown to be successful in various infectious diseases,
such as Neisseria meningitides infection, HIV (Park et al.,
2016), RSV, and tuberculosis (Paul et al., 2013). Therefore, a
potent T cell-activating peptide vaccine based on the HTNV
structural protein may be a promising method of disease control
(Ma et al., 2013).
The antigenicity of Hantaviruses largely depends on two
structural proteins, the nucleocapsid protein (NP) and envelope
glycoprotein (GP) (Zeier et al., 2005). NP is highly immunogenic,
inducing vigorous cellular and humoral immune responses in
humans, and conserved among viral species. GP is not only
responsible for receptor binding and membrane fusion, but
is also considered the main target of neutralizing antibodies
(Wang et al., 2011). T cells are essential components of the
immune response to most viral infections. Therefore, epitopes of
HTNV NP that elicit CD4+ and CD8+ cytotoxic T lymphocyte
responses have been extensively studied (Ennis et al., 1997; Van
Epps et al., 1999; Lee et al., 2002). Viral GP-specific T cell
responses have also been discovered (Ma et al., 2015). Protective
immunity elicited through infection with recombinant HTNV-
glycoprotein in murine models has also been demonstrated (Yu
et al., 2013). Recent interest has emerged in the concept of
HTNV glycoprotein serving as a potent immunogen to induce T
cell responses (Manigold et al., 2010). However, T cell epitopes
on the HTNV glycoprotein have not been fully identified,
and specific responses to these immunogens remain largely
unknown.
During viral infection, CTLs are important for viral clearance
and preventing immunopathology in humans (Kiepiela et al.,
2007). To create a mouse model for studying the role of
HTNV-specific T cells in vivo, we employed a newly identified
mouse CTL epitope on the HTNV glycoprotein. In our study,
we describe a CTL epitope on HTNV GP and analyze the
cellular immune response against HTNV. Our findings could
support the production of an effective peptide vaccine for
HTNV infection in humans. To our knowledge, this is the
first report about mouse CTL epitopes on the glycoprotein
of HTNV.
MATERIALS AND METHODS
Animals
Pathogen-free C57BL/6 female mice between 8 and 10 weeks
old were purchased from the animal research center of the
Fourth Military Medical University (Xi’an, China). The mice
were cared for in accordance with the Guide for the Care and
Use of Laboratory Animals. The animals were acclimated to the
laboratory environment for 5–7 d before use.While in their home
cage environment, the animals were allowed free access to a
standard animal diet and tap water. The room was maintained
at 20–23◦C with a 12 h/12 h light/dark cycle. The animals were
deeply anesthetized using inhaled isoflurane (1–3% or as needed)
before all operations. All efforts were made to minimize animal
suffering, to reduce the number of animals used, and to utilize
alternatives to in vivo experiments whenever appropriate or
feasible. The animal protocol was approved by the Fourth
Military Medical University Medical Ethics Committee (Xi’an,
Shaanxi, China; approval no.XJYYLL-2015510). Experiments
were performed in age-matched groups.
Viruses and Cells
HTNV strain 76–118 was obtained from our repository. EL-
4 and P815 cells, which express H-2b and H-2d as MHC
class I molecules, were obtained from American Type Culture
Collection (ATCC; Manassas, VA, USA). EL-4 cells were cultured
in Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen,
Carlsbad, CA, USA) supplemented with 10% horse serum
(HyClone, Logan, UT, USA). All other cells were maintained
in DMEM that was supplemented with 10% fetal bovine serum
(FBS) (HyClone, Logan, UT, USA).
Synthesis of Peptides
The 15 8-mer peptides used in the ELISPOT screens correspond
to the glycoprotein of HTNV strain 76–118 (Table 1). All of
these peptides were synthesized with greater than 98% purity
as determined by high-performance liquid chromatography
(HPLC) and resuspended in sterile phosphate-buffered saline
(PBS) solution containing DMSO (1mg/mL). Each peptide
is H-2Kb-restricted. HTNV nucleoprotein (NP) aa221–aa228
(SVIGFLAL) derived from the HTNV nucleoprotein was used as
a positive control epitope (Park et al., 2000). We used computer
algorithms in Immune Epitope Database and Analysis Resources
(IEDB-http://tools.iedb.org/main/) to identify optimal peptide
epitopes within the reactive 8-mer peptides.
Ex vivo IFN-γ Enzyme-Linked Immunospot
(ELISPOT) Assay
Identification of the HTNV GP-specific CTL epitopes was
performed using the IFN-γ ELISPOT assay (Mabtech, Büro
Deutschland, Germany) according to the manufacturer’s
instructions. After 7 days of infection with HTNV, mice were
sacrificed and their spleens harvested. Briefly, splenocytes were
prepared and assayed for their ability to secrete IFN-γ during in
vitro restimulation with antigenic peptides. The positive peptides
in the first round screen were subsequently characterized in
CD4- or CD8-depleted splenocytes using anti-CD4-coated
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TABLE 1 | Synthetic peptides on the glycoprotein of HTNV predicted to
bind with H2-Kb.
Serial number 8-mer Octamer Percentile_ Binding
of peptide peptide sequencea rankb scorec
GP 1 39∼46: SVIGYVEL 0.75 7.2
GP 2 44∼51 VELPPVPL 0.75 4.5
GP 3 64∼71 SMDNHQSL 0.75 7.4
GP 4 208∼215 IVCFFVAV 0.55 3.7
GP 5 420∼427 VNFVCQRV 0.5 5.7
GP 6 456∼463 ITSLFSLL 0.25 10.3
GP 7 489∼496 VTFCFGWV 0.2 6.8
GP 8 499∼506 PAITFIIL 0.5 8.1
GP 9 797∼804 ITIRYSRR 0.4 4.9
GP 10 845∼852 TLLFFGPL 0.4 8.4
GP 11 925∼932 QSFNTSTM 0.4 3.4
GP 12 987∼994 VGFTLTCL 0.5 4.3
GP 13 1102∼1109 FSGNWIVL 0.7 3.6
GP 14 1113∼1120 CVFLLFSL 0.85 4.9
GP 15 1114∼1121 VFLLFSLV 0.25 3.1
NP 1 221–228 SVIGFLAL 0.2 11.0
aCorresponding to HTNV (76–118) GP.
bA percentile rank in H-2Kb restriction, was calculated by IEDB.
cThe binding score in H-2Kb restriction, expressed as arbitrary units, was calculated by
the BIMAS software.
Dynalbeads (Invitrogen Dynal AS, Oslo, Norway) and anti-CD8-
coated Dynalbeads (Invitrogen Dynal AS, Oslo, Norway). Total
splenocytes or the isolated T cells were seeded in ELISPOT plates
at 5 × 105 cells/well and stimulated with 15 8-mer peptides
at a final concentration of 10 µg/mL. Cells with nonspecific
phytohemagglutinin stimulation (PHA, 10 µg/mL, Sigma-
Aldrich, St. Louis, MO) or without peptide stimulation served as
positive and negative controls, respectively. Additionally, spleen
cells pulsed with the immunodominant NP221–228 peptide
(Park et al., 2000) was used as an epitope positive control. For
quantification of ex vivo responses, the assay was performed in
duplicate. An automated ELISPOT reader (Cellular Technology
Limited, USA) was used to count the spots. Spot-forming cells
(SFC) were adjusted by subtracting average negative values
and expressed as SFC/106 splenocytes. A positive response was
defined as having at least 100 SFC/106 input cells. The SFC/106
splenocytes in unstimulated control wells never exceeded 5 spots
per well.
Cell-Mediated Cytotoxicity Assay
The lactate dehydrogenase (LDH)-releasing CytoTox 96
nonradioactive cytotoxicity assay (Promega, Madison, WI,
USA) was performed to detect the level of specific cytotoxicity,
as described in the manufacturer’s protocol. CD8+ T cells
isolated with anti-CD8-coated Dynalbeads from the splenocytes
of HTNV-immunized mice were used as effector cells. Target
cells used in this study were peptide-pulsed EL-4 cells, HTNV-
inoculated macrophages, and control cells (P815). Target
cells were plated at 1 × 104 cells per well in a volume of 50
µL in wells of a 96-well U-bottomed microtiter plate. The
splenocytes (effector cells) were added to a final volume of 50
µL at effector/target (E/T) ratios of 100:1, 50:1, 20:1, and 10:1.
The assay plate included the following controls: spontaneous
lactate dehydrogenase (LDH) release from effector cells alone
(50 µL of effector cells and 50 µL of 10% FBS RPMI-1640
medium), spontaneous LDH release from target cells alone (50
µL of target cells and 50 µL of 10% FBS RPMI-1640 medium),
maximum LDH release from target cells alone (50 µL of target
cells, 50 µL of 10% FBS RPMI-1640 medium and 10 µL of
the lysis solution), a volume correction control (100 µL of
10% FBS RPMI-1640 medium and 10 µL of the lysis solution),
and a culture medium background control (100 µL of 10%
FBS RPMI-1640 medium). The percentage of cells lysis was
calculated according to the following formula: % cytotoxicity
= [(E − St − Se)/(M − St)] × 100% (E, LDH release from
effector-target co-culture cells; St, spontaneous LDH release
from target cells; Se, spontaneous LDH release from effector
cells; M, maximum LDH release from target cells). All of the
CTL assays were performed in triplicate and repeated at least
twice.
Intracellular Cytokine Staining
Two million freshly isolated splenocytes from HTNV-infected
mice were stimulated for 4 h withHTNVGP-specific peptides (10
µg/mL for each peptide). Cells stimulated with PHA (0.1 µg/ml,
Sigma-Aldrich, St. Louis, MO) or medium alone were used
as positive and negative controls, respectively. After washing,
splenocytes were stained with antibodies against surface markers,
CD3-FITC and CD8-PerCP/Cy5.5 (BD Pharmingen), in different
combinations for 40 min at 4◦C, followed by washing, fixation
and permeabilization with a buffer (BD Biosciences, San Jose,
CA). The cells were subsequently stained with antibodies against
intracellular markers IFN-γ-PE (BD Pharmingen), for 40min at
4◦C, followed by washing, and acquisition using a FACS Calibur
flow cytometer (Becton Dickinson). A total of 100,000 events
per sample from the lymphocyte gate were collected for each
analysis.
Ex vivo Proliferation Assay
The CFSE-labeled proliferation assay was performed as
previously described. Briefly, 1 × 107/ml PBMCs were labeled
with 10 µM 5,6-carboxyfluorescein succinimidyl ester (CFSE,
Molecular Probes, OR) at 37◦C for 15 min. Labeling was
terminated upon the addition of fetal bovine serum and the
cells were stimulated with HTNV GP-specific peptides (10
µg/mL). Anti-mouse CD3 (Biolegend) stimulation of PBMCs
and no peptide stimulation served as positive and negative
controls, respectively. After 2 days, 10% exogenous IL-2
was added. After 5 days, the cells were harvested to detect
their expansion capacity. Approximately 100,000 cells were
acquired using a FACS Calibur (BD Immunocytometry Systems,
California).
Immunizations
As shown in Figure 5A, 8-week-old C57BL/6 (H-2b) mice (10
mice/group) were subcutaneously immunized four times with
mixed peptide vaccines at 10 day intervals. The mixed peptide
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vaccine per mouse consisted of 100 µL (100 µg) of GP6
packaged with either 100 µL complete Freund’s adjuvant (CFA)
at primary immunization or incomplete Freund’s adjuvant (IFA)
at boost immunization. Each vaccine solution was emulsified.
Four control groups were used: the first two groups were
immunized with 100 µL (100 µg) of NP 1 packaged with 100 µL
Freud’s adjuvant or 200 µL (100 µg) of commercially purchased
inactivated Hantavirus vaccine (Tianyuan, Hangzhou, Zhejiang,
China) per mouse; and the other two groups were given either
200 µL of PBS or 200 µL of Freud’s adjuvant per mouse. At
10 d after the last immunization, 5 mice of each group were
sacrificed and their splenocytes were isolated for subsequent
assays.
Animal Challenge/Protection Assay
At 10 d after the final boost immunization, the remaining mice
of each group received an infectious dose (1× 105 pfu/mouse) of
HTNV strain 76–118 intramuscularly. After 3 days of infection,
the mice were killed, and the major tissues, including the heart,
liver, spleen, lung, kidney, and cerebrum, were individually
collected for subsequent assays.
Detection of HTNV Antigens in Mouse Tissues by
ELISA
Each tissue sample was weighed, diluted in PBS, ground, and then
freeze-thawed (−80/37◦C) three times to prepare a 10% (g/mL)
tissue suspension. The suspension was centrifuged at 12,000 rpm
for 10min at 4◦C to collect the supernatant. HTNV antigens in
the supernatant were detected by sandwich ELISA. The mAb 1A8
was used as a coating antibody, and HRP-conjugated 1A8 was
used as the detecting antibody. Normal tissue supernatant was
used as a negative control. The absorbance was measured at a
wavelength of 450 nm using a Synergy HT ELISA plate reader
(Biotec, Dresden, Germany). Absorbance of >0.1 was required
as positive and positive/negative (P/N) >2.1 was considered
significant.
HTNV Nucleic Acid Detection in Tissues by qRT-PCR
Total cellular RNA was extracted from each tissue sample
using an RNAprep Pure Tissue Kit (Tiangen, Beijing, China),
then 1 µg of total cellular RNA from each sample was used
in a qRT-PCR using a SYBR Premix Ex Taq II Kit and
the following HTNV RNA-specific primers: HTNV (forward)
5′-GATCAGTCACAGTCTAGTCA-3′ and HTNV (reverse) 5′-
TGATTCTTCCACCATTTTGT-3′. GAPDH was included in the
qRT-PCR as an internal control for cellular RNA using the
following mouse GAPDH-specific primers: GAPDH (forward)
5′-AGGCCGGTGCTGAGTATG TC-3′ and GAPDH (reverse)
5′-TGCCTGCTTCACCACCTTCT-3′.
Histopathological Analysis
Each tissue sample was embedded in a paraffin block and cut
with a microtome into 5-µm sections, which were subsequently
mounted onto glass slides and stained with hematoxylin and
eosin (H&E).
Flow Cytometric Analysis
Flow cytometric analysis was performed immediately with
FlowJo version 9.2 (TreeStar). FITC-, PE-, and PerCP-Cy5.5-
conjugated mouse IgG1, κ were used as isotype controls of the
3-color staining method. Lymphocytes were defined by FSC/SSC,
and CD8+ T cells were defined as CD3+CD8+ events, which
were then displayed on flow cytometric plot. The cytokine
response was considered positive when the percentage of cells
producing the cytokine was greater than 0.1% after background
subtraction.
Statistical Analysis
Data were analyzed for statistical significance using GraphPad
Prism 5 software. All data are expressed as the mean ± the
standard error of mean (SEM) and are representative of at
least three independent experiments. Comparisons of positive
rate were analyzed by one way ANOVA. Results of ELISPOT
assay were compared by one way ANOVA, and CTL assay
was compared using two way ANOVA. Protective efficacy was
compared using one way ANOVA. A p-value of 0.05 or less was
considered significant.
RESULTS
Identification of Novel H-2Kb-Restricted
CTL Epitopes within the Glycoprotein of
HTNV by ELISPOT Assay
To examine the T cell responses specific for HTNV-glycoprotein
in C57BL/6 mice, we first screened T cell epitopes on HTNV-
glycoprotein. Splenocytes isolated from HTNV-infected mice
were tested against each peptide by enumeration of peptide-
specific IFN-γ SFC using an ex vivo ELISPOT assay. Peptides
GP1, GP2, GP3, GP6, GP8, and GP10 were found to induce
IFN-γ production with a spot magnitude of 225, 130, 257,
461, 196, and 162 SFC/106 input cells, respectively, whereas the
remaining peptides only elicited a weak response (Figure 1A).
Notably, the GP6 peptide elicited the strongest IFN-γ response
among the various peptides tested, with a frequency of 461
SFC/106 input cells, which was similar to the 516 SFC/106
input cells of NP1. This finding indicates that six of 15
HTNV GP-specific peptides could induce a strong IFN-γ
response.
Then, to determine a more precise understanding of the
epitope-specific T cell responses, CD4+ or CD8+ T cell-
depleted splenocytes from HTNV-infected mice were employed
as effector cells. The results showed that one peptide (GP6
aa456∼463: ITSLFSLL) induced significant numbers of IFN-γ-
producing cells in CD4+ T cell-depleted cultures and limited
the response magnitude in CD8+ T cell-depleted cultures. GP6
peptide induced a significantly higher numbers of IFN-γ spots
in total splenocytes cultures compared to the spots in CD8+
T cell-depleted cultures (p < 0.0001), but significant difference
has not been observed when compared to the spots in CD4+
T cell-depleted cultures. This finding confirms that GP6 is a
CTL epitope on HTNV GP. However, CD4+ T cell depletion
completely abrogated the IFN-γ responses induced by another 5
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FIGURE 1 | Identification of an HTNV GP-specific CD8+ T cell epitope by IFN-γ ELISPOT assay. (A) IFN-γ ELISPOT analysis of splenocytes obtained 7 d
after HTNV infection (n = 6). Cells were stimulated with 15 8-mer peptides corresponding to HTNV glycoprotein. (B) IFN-γ ELISPOT analysis of splenocytes obtained
7 d after infection (n = 6) with the depletion of CD4+ T cells (CD4 depleted SP) and CD8+ T cells (CD8 depleted SP) or without depletion (Total SP). ***P < 0.0001.
peptides (GP1, GP2, GP3, GP8, and GP10; Figure 1B), indicating
that these peptides are CD4+ T cell epitopes that could be
immunodominant.
The Cytotoxic Capacity of HTNV
Glycoprotein-Specific CD8+ T Cells
To further characterize the GP6 peptide as a CTL epitope,
cytotoxic assays using GP6 and NP1 were performed. As
described in methods, HTNV-infected macrophages, peptide-
pulsed EL-4 cells and P815 cells (control cells) were used as target
cells. As shown in Figure 2A, EL-4 cells pulsed with GP6 were
killed by primary antiviral CTLs, with cell death percentages of
25.5, 19.3, 13.2, and 10.5% at E/T ratios of 100:1, 50:1, 20:1, and
10:1, respectively. The NP1 peptide sensitized target cells for lysis
by anti-HTNV CTLs, with percentages of 33.5, 21.7, 15.5, and
10.2% at E/T ratios of 100:1, 50:1, 20:1, and 10:1, respectively
(Figure 2B). As endogenous target cells, the HTNV-infected
macrophages were also lysed by the primary antiviral CTLs at
higher rates of 41.4, 32.7, 20.8, and 15.8%, at each E/T ratio
mentioned above, respectively. These results indicate that GP6
can elicit CTL responses and plays a role in the primary antiviral
response of HTNV-infected mice.
A second cell-mediated cytotoxicity assay was performed
to evaluate whether GP6 could enhance peptide-specific
cytotoxicity of CTLs. Splenocytes from HTNV-infected mice
were restimulated in vitro with GP6 and NP1. Figure 2C
shows that restimulation with GP6 resulted in strong CTL
responses with percentages of cell death of 63.2, 58.6, 50.3,
and 31.2% at E/T ratios of 100:1, 50:1, 20:1, and 10:1,
respectively. NP1 peptide-specific cytotoxicity was greater with
higher percentages of 71.1, 59.6, 53.9, and 45.9%, respectively
(Figure 2D). Although, GP6 induced a relatively weaker CTL
response compared to NP1, this peptide caused strong cytotoxic
activity, which was especially significant at the E/T ratios of
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FIGURE 2 | Cytotoxic activity of splenocytes derived from HTNV-infected mice in vitro. The primary antiviral CTL responses were first detected. Splenocytes
from C57BL/6 mice infected with HTNV (1 × 105 pfu/head) were used as effector cells. As targets, EL-4 cells were pulsed with GP6 (A) and NP1 (B) at a
concentration of 10 µg/mL. Splenocytes that were restimulated with GP6 (C) and NP1 (D) were used as effector cells in the second round of the CTL assay.
Macrophages infected with HTNV () and peptide-pulsed EL-4 cells (•) were used as target cells. P815 cells (N) were used as negative controls. (E) Evaluation of the
mean lysis percentage of naïve CD8+T cells to kill no peptide-pulsed target cells. Macrophages (), EL-4 cells (•), and P815 cells (N) were served as target cells,
respectively. Data are expressed as the mean ± SEM (n = 6). **P < 0.001, ***P < 0.0001.
50:1 and 20:1. Significant CTL activity could not be found
in the non-specific group (Figure 2E). Other peptides were
also tested, but CTL activity was undetectable. Collectively,
these results suggest that the GP6 peptide is able to provide
restimulation for primary antiviral CTLs to maintain specific
cytotoxicity ability.
Effector Functions of HTNV GP
Epitope-Specific CD8+T Cells
Given the importance of IFN-γ production in the defense against
HTNV infection, we further investigated the production of IFN-γ
by CD8+ T cells specific for HTNV GP by intracellular cytokine
staining. This assay showed that the GP6 peptide induced a high
percentage of IFN-γ production among CD8+ T cells (11.97%
of total CD8+T cells). The frequency of IFN-γ-producing cells
upon recognition of NP1 peptide was also observed (15.98% of
total CD8+T cells). CD8+T cells restimulated with PHA also
showed a high level of IFN-γ secretion with 15.25 percent of
the total. However, a few cells producing IFN-γ were detected
in both negative control groups (4.64% of total CD8+T cells
in mock-infected mice with no peptide restimulation and
4.73% of total CD8+T cells in HTNV-infected mice with no
peptide restimulation; Figure 3A). This assay was performed
and repeated six times. We have given the statistical results
in Figure 3B. HTNV-infected mice with GP6 restimulation
group induced a significantly IFN-γ response compared to both
negative control groups (the mock-infected mice with no peptide
restimulation, p < 0.0001; HTNV-infected mice with no peptide
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FIGURE 3 | The rapid secretion of IFN-γ after recognition of the HTNV-specific peptide. (A) Representative flow cytometric plots of IFN-γ production by
peptide-specific CD8+ T cells. The upper lane (A) shows the results 4 h after peptide restimulation and both negative and positive controls, and the lower lane
(B) shows the frequency of IFN-γ production in CD8+ T cell populations. Data are expressed as the mean ± SEM (n = 6). ***P < 0.0001.
restimulation, p < 0.0001). Our result is consistent with the data
obtained in the ELISPOT assay (Figure 1).
Ex vivo CD8+ T Cell Expansion against
HTNV Glycoprotein
We next assessed whether the antiviral effect of CTLs was
dependent on the capacity of expansion. The CFSE staining
assay showed that expansion of HTNV peptide-specific CTLs
was readily detectable. As shown in Figure 4, PBMCs of HTNV-
infected mice after stimulation with GP6 had a considerable
expansion potential with 49.23% cells belonging to Generation 3
(Figure 4A). A similar level of expansion potential was observed
in the NP1 stimulation group (Figure 4B). However, when
stimulated with anti-mouse CD3 as a control, PBMCs had
proliferative activity with 59.1% of cells belonging to Generation
3 (Figure 4C), which was higher than cells stimulated with
HTNV-specific epitopes. The negative control of no peptide
stimulation showed a low expansion coefficient with 39.99%
(Figure 4D). The statistical results were provided in Figure 4E.
HTNV-immunized mice with GP6 stimulation group showed
a significant proliferation ability compared to the group with
no peptide stimulation (P < 0.05). Previous studies have
demonstrated a strong linkage between HTNV-specific CD8+T
cell expansion and the control of HTNV infection. These data
demonstrate the proliferative potential and capacity of specific
CD8+ T cells in protecting from HTNV infection.
Immunization with HTNV CTL Epitope
Peptides Elicited an Enhanced Cellular
Immune Response in Mice
First, we measured cytokine production by ELISPOT assay as an
indicator of cellular immune responses to reflect T cell responses
to HTNV GP peptides. As shown in Figure 5B, splenocytes
from GP6 peptide-immunized mice, restimulated with purified
HTNV NP, presented a significantly higher number of IFN-γ
spots compared to both the HTNV NP1-immunized group and
inactivated Hantavirus vaccine group. HTNV-immunized mice
showed the highest number. In contrast, we also observed that
the numbers of IFN-γ spots from the two negative control groups
(resolver control and adjuvant control) were extremely low.
Next, the GP peptide-specific CTL activity was detected by
an LDH release assay. The cytotoxicity of splenocytes from mice
immunized with GP6 was enhanced in accordance with the
E/T ratio, which was the most significant at the ratio of 100:1
(Figure 5C). Splenocytes from the NP1-immunized mice showed
the highest specific cytotoxic activity at E/T ratios of 100:1, 50:1,
and 20:1 compared to those of the other groups. Additionally,
the specific cytotoxic activities were not significant in the vaccine
group. Perhaps, poor immunogenicity of these vaccines to elicit
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FIGURE 4 | The proliferative capacity of HTNV peptide-specific CD8+ T cells. Representative flow cytometric histogram of the expansion percentage of CD8+
T cells stimulated by the GP6 (A) and NP1 (B). Anti-mouse CD3 (Biolegend) (D) stimulation or no peptide (C) stimulation served as positive or negative controls,
respectively. (E) The statistical data of the proliferation assay. Data are expressed as the mean percentage ± SEM (n = 6). *P < 0.05.
cell-mediated immunity is the main cause. However, non-specific
cytotoxicity in the two negative control groups was extremely
weak at E/T ratios of 100:1, 50:1, and 20:1.
Based on these results, immunization with GP6 peptide
induced a high level of IFN-γ response and strongly
specific cytotoxic activity, suggesting that immunization
with HTNV-GP specific peptides enhances cellular immune
responses.
Immunization with Recombinant CTL
Epitope Peptides Induced Protective
Immunity in C57BL/6 Mice against HTNV
Challenge
Protective immunity was evaluated in peptide-immunized mice.
Three days after infection with HTNV, the major tissues of the
mice were isolated to test against HTNV antigens by ELISA. We
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FIGURE 5 | The enhanced cellular immune responses in peptide-immune C57BL/6 and the timeline of immunization. (A) Scheme of peptide immunization.
Mice were primed and boosted with GP6 and NP1 packaged with Freud’s adjuvants (Pep Immun group) or PBS (Mock group). Ten days after the final boost,
splenocytes from mice were harvested for subsequent assays. (B) IFN-γ ELISPOT analysis of splenocytes obtained from HTNV peptide-immunized mice. Cells were
stimulated with purified HTNV NP. (C) Splenocytes from immunized mice, restimulated with relative peptide were used as effector cells. As targets, EL-4 cells were
pulsed with GP6 or NP1 at a concentration of 10 µg/ml. () represents NP1 immunization; (•) represents GP6 immunization; (N) represents a positive control from the
HTNV-challenged mice; () represents vaccine control; (◦) represents PBS control; (H) represents adjuvant control. Data are expressed as the mean ± SEM (n = 6).
***P < 0.0001.
found that HTNV antigens were detected in the liver, spleen,
and kidney of C57BL/6 mice in both negative control groups
(adjuvant control and PBS control; P/N = 10.49, 11.57, and 5.13
in adjuvant control group or 9.89, 11.3, and 4.89 in PBS control
group, respectively). However, antigens could not be detected in
the liver, spleen or kidney of mice in the inactivated Hantavirus
vaccine control group. Interestingly, this method detected lesser
amounts of HTNV antigens in the liver, spleen and kidney of
GP6-immunized mice compared with negative control groups
that had absolutely no protection (P/N = 5.01, 4.90, and 2.57,
respectively). Additionally, the HTNV antigens in NP1 peptide-
immunized mice were found at low values of 3.67, 4.15, and 2.74,
respectively. HTNV-specific antigens could not be detected in
the heart, lung, or cerebrum of C57BL/6 mice from all of the
groups (Figure 6). These results indicate that the immunization
of C57BL/6mice with the recombinant positive peptides provides
protective immunity against HTNV challenge.
Meanwhile, the qRT-PCR assay was used to detect HTNV
nucleic acids in the tissues of peptide-immunized C57BL/6 mice
after challenge with HTNV. HTNV nucleic acids were detected
in the liver, spleen, and kidney of C57BL/6 mice in the two
negative groups with 11.43-, 13.5,- and 4.63-fold or 10.96-,
13.6,- and 5.57-fold amplification, respectively, compared to the
inactivated Hantavirus vaccine group which did not contain viral
nucleic acids. Small amounts of HTNV-specific nucleic acids
were detected in the same tissues of C57BL/6 mice from the GP6-
or NP1-immunized groups, compared to the negative controls
(Figures 7C,D,F). Moreover, HTNV-specific nucleic acids could
not be detected in other tissues of C57BL/6 mice in all of the
groups (Figures 7A,B,E). These results were consistent with the
ELISA results.
Histopathological analysis by H&E staining showed that no
significant alterations were found in the tissues from all of the
groups except for the spleens of the two negative control groups
(PBS control and adjuvant control). The results indicated some
pathological changes including diffused lymphocyte infiltration,
diffused hemorrhaging and increased white pulp in the spleens
of the two negative control groups (PBS control and adjuvant
control) which weremarked with red arrows in the Figures 8D,E;
however, these changes were not found in the other groups
(Figure 8).
Taken together, these results show that immunization with the
recombinant positive peptides induces protective immunity in
C57BL/6 mice against HTNV challenge.
DISCUSSION
Vaccines, collectively a successful strategy for the prevention
of infectious diseases, can direct the host’s immune system
against pathogens (Ma et al., 2016). Inactivated vaccines for
HTNV have been shown to boost the humoral immune
response (Kumar et al., 1997), but poor immunogenicity
in eliciting neutralizing antibodies and limited cell-mediated
immunity following vaccination, as well as concern regarding
safety are major obstacles for development (Yang et al., 2005).
Therefore, inactivated vaccines are not expected to be able to
effectively inhibit HTNV amplification to completely prevent
viral infection (Yang et al., 2005). A potent T cell-activating
peptide vaccine based on the HTNV structural protein may
be a promising strategy for disease control (Rubsamen et al.,
2014; Lu et al., 2016). The T cell response is a critical element
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FIGURE 6 | Detection of HTNV-specific antigens from peptide-immunized mice by ELISA. ELISA was used to detect HTNV antigens in the tissues of each
group including the cerebrum (A), heart (B), liver (C), spleen (D), lung (E), and kidney (F). (•) represents the GP6 peptide-immunized group; () represents the NP1
peptide-immunized group; (N) represents the inactivated Hantavirus vaccine control group; (◦) represents the PBS control group; () represents the adjuvant control
group. Data are expressed as the mean ± SEM (n = 4). *P < 0.05, **P < 0.001.
FIGURE 7 | qRT-PCR results of HTNV-specific nucleic acids in organs of peptide-immunized mice. This method detected HTNV nucleic acid in the tissues
of each group including the cerebrum (A), heart (B), liver (C), spleen (D), lung (E), and kidney (F). The viral nucleic acids are distributed mainly in the spleen and liver,
but to a lesser degree in the kidney. Data are expressed as the mean ± SEM (n = 6). **P < 0.001, ***P < 0.0001.
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FIGURE 8 | Histopathological analysis of the spleens from
peptide-immunized mice after challenge with HTNV by H&E staining.
(A) The GP6 peptide-immunized group. (B) The NP1 peptide-immunized
group. (C) The inactivated Hantavirus vaccine group. (D) The PBS control
group. (E) The adjuvant control. Red arrows show diffused lymphocyte
infiltration, diffused hemorrhaging and increased white pulp in the spleens of
two control groups.
of naturally acquired immunity to control viral infection,
including HTNV infection (Rasmuson et al., 2011). This
fact provided the theoretical basis for the development of
HTNV peptide vaccines to fight infection by inducing specific
T cell responses. In this study, we reported that the GP6
peptide derived from glycoprotein of HTNV could be an
immunogenic epitope based on its ability to induce peptide-
specific CD8+ T cell responses and on in vivo functional
validation. We further provided evidence that immunization
with GP6 in C57BL/6 mice successfully induced T cell responses
with high production of IFN-γ and potent cytotoxicity, which
involved in combatting HTNV infection after HTNV challenge.
This reveals that GP6 peptide may be a good candidate for
use as a peptide-based vaccine in the design of preclinical
studies in vivo.
Identification of the Correct CTL Epitopes
within the Glycoprotein of HTNV by
ELISPOT Assay
Selecting the correct epitope is a priority when designing
an effective vaccine. An epitope, which is the portion of an
antigen presented on major histocompatibility complex (MHC)
molecules that bind the TCR or BCR of T/B lymphocytes,
initiates, and evokes T/B cell immune responses (Hoffmeister,
2003). First, we evaluated the sequence of the HTNVGP using an
algorithm, provided by IEDB of the National Institute of Allergy
and Infectious Diseases (Vita et al., 2015). We selected and
synthesized 15 peptides and tested their respective antigenicity
according to binding score. A higher score means a stronger bind
to MHC (Park et al., 2000). This first crucial step increases the
probability of successful epitope selection. The high production
of antiviral cytokines is a critical characteristic of effective
T cell immunity for both suppressing viral replication and
eliminating virus-infected host cells. IFN-γ has been implicated
in immune regulation and direct antiviral activities (Frese et al.,
2002; Gattoni et al., 2006). Therefore, the IFN-γ ELISPOT was
conducted for mapping the epitopes of HTNV glycoprotein. In
the first round of the ELISPOT assay, six of 15 peptides could
induce a strong IFN-γ response, but this datum does not illustrate
that the peptides are CTL epitopes. Taking the complexity of
IFN-γ-secreting cells into consideration, the second round of the
ELISPOT assay was performed using both CD4+ T cell-depleted
splenocytes and CD8+ T cell-depleted splenocytes as effector
cells.We tried to use CD4+ T cell-depleted splenocytes as effector
cells to recognize the CD8+T cell responsive 8-mer epitopes.
On the other hand, CD8+ T cell depletion completely abrogated
the IFN-γ response indicating that these peptides were CD8+
T cell epitopes. The data showed that HTNV GP6 induced the
largest number of IFN-γ-producing cells (over 450 cells per
106 splenocytes) with CD4 depletion and a small quantity with
CD8 depletion (less than 40 cells per 106 splenocytes) among
the 15 alternative peptides. These data are consistent with that
of NP1, which also induced a significant number of IFN-γ-
producing cells (over 470 cells per 106 splenocytes) when CD4+T
cells were depleted and <35 SFC when CD8 cells were depleted
(Figure 1B). However, other peptides did not induce detectable
levels of IFN-γ-producing cells when the CD4+ T cells were
depleted. Based on this finding, we speculate that GP6 might be
an immunodominant CTL epitope.
Detection of the Cytotoxicity of HTNV
Epitope-Specific CD8+ T Cells by CTL
Assays
CTL assays were performed to evaluate peptide-specific cytotoxic
activity. The data suggested that GP6 elicits a CTL response
and also plays a key role in the primary antiviral response
during HTNV infection in mice. To examine whether this
peptide could enhance peptide-specific cytotoxicity of CTLs, we
measured secondary CTL responses after in vitro restimulation.
After secondary stimulation with the GP6 peptide, CTL activity
against the relevant peptide was increased. At the same time,
we also used HTNV-infected macrophages as the endogenous
target cells to evaluate whether the peptide-specific CTLs
could effectively recognize endogenously processed antigen.
The results showed a high level of cytotoxic activity of GP6-
specific CTLs even when using the endogenous cells as targets.
This suggests that GP6 could be processed and presented
by endogenously antigen-presenting system. These results also
imply that GP6 can provide restimulation to maintain the
cytotoxic activity of primary antiviral CTLs and have the
potential to induce T lymphocyte responses during viral
infection.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 11 November 2016 | Volume 6 | Article 151
Ma et al. Identification of the HTNV-GP CTL-Epitope
CTL Epitope from HTNV Glycoprotein
Provided Significantly Enhanced
Immunogenicity over Inactivated HTNV
Vaccine
To evaluate the immunogenicity of the identified epitopes from
our study ex vivo, the cellular immune response was evaluated
at 10 d after the final booster immunization with the specific
epitope in C57BL/6mice. Our results showed that the splenocytes
of GP6 group mice always showed stronger T cell responses
compared with the other groups. Meanwhile, the splenocytes of
the vaccine control group have a weak magnitude of response
of T cells, particularly because of the poor immunogenicity of
inactivated Hantavirus vaccine to elicit cell-mediated immunity
(Kwilas et al., 2014). Our results verified this point again.
The CTL Epitope-Vaccinated Mice
Presented Partial Protection Immunity
from Challenge with HTNV
We further provided evidence of the potential capacity of
the identified epitopes to protect mice after HTNV challenge
through the animal protection assay. Viral load in each of the
major organs of C57BL/6 mice served as parameters to assess
protection. Based upon the peak of viral replication, the mice
were sacrificed 3 days post-challenge. Using ELISA and qRT-
PCR, we found that large amounts of HTNV antigens and
nucleic acid could be detected in the spleen, liver, and kidney of
C57BL/6 mice in the two negative control groups (PBS control
and adjuvant control), but not in the vaccine group. Further
comparisons revealed that viral antigens and nucleic acids in
the spleen were higher than those in the liver and kidney. It
was interesting to note that viral antigens and nucleic acids can
only be detected in small amounts in the GP6 and NP1 groups.
The data from histopathological analysis by H&E staining also
showed some pathological changes in the spleens (Figure 8) of
mice belonging to the two negative control groups (PBS control
and adjuvant control) but not in vaccine groups after challenge
with HTNV. Although, the level of HTNV nucleic acids and
antigens in the GP6 group was greater than those in the vaccine
group, the potential capacity of GP6, as an 8-mer aa peptide
existing on the huge HTNV structure, to protect mice from
HTNV infection cannot be ignored. These findings suggests that
GP6-specific CTL response could protect animals from HTNV
challenge.
An Excellent Method to Evaluate Protective
Therapeutic Agent for HTNV
Our goal was to identify CTL epitopes on HTNV GP in
mice to gain a better understanding of the recognition of
HTNV by cellular immune responses, and we found that
GP6 could be applied to vaccine design preclinical studies
of vaccines that target T cell immunity. HTNV infection
in adult mice results in transient viral replication with no
symptoms followed by the elimination of virus (Araki et al.,
2004). However, HFRS is a severe, life-threatening illness
characterized by fever, hemorrhage, and renal failure (Serikawa
and Yamada, 1993). Due to limitations of using a model
for disease progression, suitable animal models that mimic
HFRS are presently unavailable. Our research is based on
detecting the viral antigens and nucleic acid to evaluate
the protective ability of viral epitopes, and this method can
also be used to evaluate each protective therapeutic agent
for HTNV.
In summary, one novel CTL epitope peptide GP6 aa456-
aa463 (ITSLFSLL) was identified in this study. As far as we
know, this is the first report of a CTL epitope on HTNV
glycoprotein in mice and we confirmed that the HTNV-
specific GP6 peptide is a highly immunogenic epitope restricted
by H-2Kb. By challenging C57BL/6 mice with HTNV in
vivo, we revealed the immunogenicity of vaccination with
the HTNV GP6 peptide and the antiviral efficiency of GP6-
specific CTL responses. But our present work only find
the CTL epitope on HTNV GP, we should learn more
about other epitopes on HTNV GP and NP (such as
neutralizing epitope) and the immunological characteristics of
their combined application in the next step. Our findings
could make some contributions to the establishment of
HFRS animal model and research on HFRS multiple peptides
vaccine.
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